rilvegostomig + gemcitabine + cisplatin

**Rilvegostomig + gemcitabine + cisplatin** is a combination regimen currently under clinical investigation, particularly in the ARTEMIDE-Biliary01 Phase III clinical trial for the adjuvant treatment of patients with biliary tract cancer (BTC) who have undergone surgical resection[1][3]. Rilvegostomig is a bispecific monoclonal antibody that targets both the PD-1 (programmed death-1) and TIGIT (T cell immunoreceptor with Ig and ITIM domains) immune checkpoints, enhancing anti-tumor immune response by blocking two major suppressive pathways used by cancer to evade immune detection[1][2][3]. By combining rilvegostomig with standard cytotoxic chemotherapeutics gemcitabine and cisplatin, the regimen aims to synergistically improve cancer cell eradication: rilvegostomig reinvigorates immune-mediated destruction, while gemcitabine and cisplatin directly kill rapidly dividing tumor cells[1][3]. The regimen is administered intravenously. Rilvegostomig is developed by AstraZeneca, derived from Compugen’s antibody technology[2].

Other names

cisplatin + gemcitabine + AZD2936CISGEM + Rilvegostomig